Alhashemi Mohsen, Alkhamis Ahmed, Jamal Mohammad, Almahmeed Husain, Hamshari Fatima, Dsouza Carol, Al-Hassani Sara, Almousawi Ahmed, Qasem Wafaa
Kuwait University, Kuwait City, Kuwait.
The Clinic, Kuwait, Kuwait.
Obes Surg. 2024 Dec;34(12):4482-4489. doi: 10.1007/s11695-024-07524-7. Epub 2024 Oct 2.
The aim of the study is to compare weight loss and safety outcomes of two different commonly available fluid-filled intragastric balloons (IGBs) used for weight loss.
A retrospective cohort study of a prospectively maintained database of adult patients who underwent IGB insertion between July 2020 and November 2021 in a single private clinic in Kuwait. The patient either received the Elipse™ or Orbera365™ balloon and was followed until the end of treatment.
A total of 358 patients were included, of which 265 and 93 each received the Elipse and Orbera365 balloons, respectively. The mean age of patients was 32.8 (SD 9), the mean body mass index (BMI) was 35 kg/m (SD 4.8), and 72.1% of patients were female. In the Elipse group, 254 patients completed treatment, and 84 patients completed the treatment with Orbera365. Weight loss outcomes were measured at the end of treatment: 4 months after Elipse insertion, and 12 months after Orbera365 insertion. Interim 4 months weight loss outcomes were also measured for the Orbera365 balloon. Patients in the Orbera365 group had significantly better total body weight loss (%TBWL, 14.7 kg [SD 8.9]) compared to the Elipse group (%TBWL 10 kg, [SD 5.6], p ≤ 0.0001) at the end of treatment, while there was no difference in weight loss outcomes between the two balloons at 4 months. There were more complications requiring premature balloon removal in the Orbera365 group (9.7%) compared to the Elipse group (3.4%).
IGBs provide significant weight loss with an acceptable safety profile. The Orbera365 ballon shows better weight loss outcomes compared to the Elipse, likely due to longer duration of treatment. However, there was a higher rate of complications requiring premature balloon removal in the Orbera365 group. Studies with larger patient cohort is needed to verify the findings of this study.
本研究旨在比较两种不同的常用充液式胃内气球（IGB）用于减肥的体重减轻情况和安全性结果。
对科威特一家私人诊所2020年7月至2021年11月期间接受IGB植入的成年患者的前瞻性维护数据库进行回顾性队列研究。患者接受了Elipse™或Orbera365™气球治疗，并随访至治疗结束。
共纳入358例患者，其中265例和93例分别接受了Elipse和Orbera365气球治疗。患者的平均年龄为32.8岁（标准差9），平均体重指数（BMI）为35kg/m（标准差4.8），72.1%的患者为女性。在Elipse组中，254例患者完成了治疗，84例患者完成了Orbera365治疗。在治疗结束时测量体重减轻结果：Elipse植入后4个月，Orbera365植入后12个月。还测量了Orbera365气球植入后4个月的中期体重减轻结果。在治疗结束时，Orbera365组患者的总体重减轻（%TBWL，14.7kg[标准差8.9]）明显优于Elipse组（%TBWL 10kg，[标准差5.6]，p≤0.0001），而在4个月时两个气球的体重减轻结果没有差异。与Elipse组（3.4%）相比，Orbera365组需要提前取出气球的并发症更多（9.7%）。
IGB可显著减轻体重，安全性可接受。与Elipse相比，Orbera365气球显示出更好的体重减轻效果，可能是由于治疗时间更长。然而，Orbera365组需要提前取出气球的并发症发生率更高。需要更大患者队列的研究来验证本研究的结果。
